Deconstructing cancer with precision genome editing

Grace A Johnson; Samuel I Gould; Francisco J Sánchez-Rivera

doi:10.1042/BST20230984

Deconstructing cancer with precision genome editing

Biochem Soc Trans. 2024 Apr 24;52(2):803-819. doi: 10.1042/BST20230984.

Authors

Grace A Johnson^#^{1

2}, Samuel I Gould^#^{1

2}, Francisco J Sánchez-Rivera^{1

2}

Affiliations

¹ Department of Biology, Massachusetts Institute of Technology, Cambridge 02142, MA, U.S.A.
² David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge 02142, MA, U.S.A.

^# Contributed equally.

Abstract

Recent advances in genome editing technologies are allowing investigators to engineer and study cancer-associated mutations in their endogenous genetic contexts with high precision and efficiency. Of these, base editing and prime editing are quickly becoming gold-standards in the field due to their versatility and scalability. Here, we review the merits and limitations of these precision genome editing technologies, their application to modern cancer research, and speculate how these could be integrated to address future directions in the field.

Keywords: CRISPR; functional genomics; genetics; genome editing; genomics; mouse models.

Publication types

Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Animals
CRISPR-Cas Systems*
Gene Editing* / methods
Genome, Human
Humans
Mutation
Neoplasms* / genetics
Neoplasms* / therapy
Precision Medicine

Abstract

Publication types

MeSH terms

Grants and funding